December 30th, 2016
The Government of Canada is seeking the views of Canadians on the proposed elimination of tariffs on certain pharmaceutical products under a World Trade Organization (WTO) arrangement.
This is being considered under a proposed fifth review of the 1994 Record of Discussion on Trade in Pharmaceutical Products (the "arrangement") concluded among the following WTO members: Canada, the European Union (EU), Japan, Macao (China), Norway, Switzerland, and the United States.
Pursuant to the 1994 arrangement, participating WTO members have eliminated their duties, on a Most Favoured Nation basis, for specified pharmaceutical ingredients and intermediates.
The original arrangement covered over 6 000 pharmaceutical-related products. To expand the coverage of tariff elimination to new pharmaceutical-related products developed after 1994, the Record of Discussion provides for the periodic review of the product coverage. Four earlier reviews occurred in 1996, 1998, 2007 and 2010. As a result of the reviews, the arrangement currently covers nearly 9 000 pharmaceutical-related products.
With respect to a fifth review of the arrangement, it has been suggested that the coverage of the arrangement be expanded to include additional compounds published by the World Health Organization (WHO) as Proposed International Nonproprietary Names.
The Government of Canada is seeking to identify the interests of Canadians in terms of product coverage as well as any concerns with the proposed elimination of Canadian tariffs for these products.
Link: Consultations on the fifth review of the Record of Discussion on Trade in Pharmaceutical Products